Apellis Receives EMA Orphan Drug Designation for APL-2 in PNH
In AllC3 inhibitor is in development for the treatment of PNH, both in patients not previously treated with eculizumab, and in patients who continue to experience hemolysis and require RBC transfusions despite receiving treatment with eculizumab. Louisville, Ky. – Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company…